Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Moriarty · SciRah

Researcher profile · Semantic Scholar

P. Moriarty

Share profile

P. Moriarty — researcher profile on SciRah

h-index: 50
Works: 207
Citations: 12K

Most-cited papers

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
F. Kronenberg, S. Mora, E. Stroes, B. Ference +18 more
2022European Heart Journal1,254 citations Open access
Semantic Scholar
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
S. Tsimikas, E. Karwatowska-Prokopczuk, I. Gouni-Berthold, J. Tardif +11 more
2020New England Journal of Medicine890 citations Open access
Semantic Scholar
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Steven E. Nissen, A. Lincoff, D. Brennan, Kausik K. Ray +25 more
2023New England Journal of Medicine732 citations Open access
Semantic Scholar
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
V. Bittner, M. Szarek, P. Aylward, Deepak L. Bhatt +21 more
2020Journal of the American College of Cardiology491 citations Open access
Semantic Scholar
Unmet Needs in Understanding Lipoprotein(a) Pathophysiology: NHLBI Working Group Recommendations to Reduce Risk of Cardiovascular Disease and Aortic Stenosis
S. Tsimikas, S. Fazio, K. Ferdinand, H. Ginsberg +12 more
2018Journal of the American College of Cardiology450 citations Open access
Semantic Scholar
The Role of Nutraceuticals in Statin Intolerant Patients.
M. Banach, Angelo M. Patti, R. V. Giglio, A. Cicero +33 more
2018Journal of the American College of Cardiology244 citations Open access
Semantic Scholar
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
M. Koren, P. Moriarty, S. Baum, J. Neutel +15 more
2022Nature Medicine211 citations
Semantic Scholar
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
P. Moriarty, Klaus G. Parhofer, Stephan P. Babirak, M. Cornier +12 more
2016European Heart Journal187 citations Open access
Semantic Scholar
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
M. Szarek, V. Bittner, P. Aylward, M. Baccara-Dinet +18 more
2020European Heart Journal184 citations Open access
Semantic Scholar
Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
R. Rosenson, S. Baker, M. Banach, K. Borow +15 more
2017Journal of the American College of Cardiology183 citations Open access
Semantic Scholar
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
I. Gouni-Berthold, V. Alexander, Qing-Qing Yang, E. Hurh +9 more
2021The Lancet Diabetes and Endocrinology154 citations Open access
Semantic Scholar
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
R. Rosenson, D. Gaudet, C. Ballantyne, S. Baum +13 more
2023Nature Medicine127 citations Open access
Semantic Scholar
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4.
S. Tsimikas, P. Moriarty, E. Stroes
2021Journal of the American College of Cardiology127 citations Open access
Semantic Scholar
The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP).
Fjolla Zhubi-Bakija, Gani Bajraktari, I. Bytyçi, D. Mikhailidis +72 more
2020Clinical Nutrition120 citations Open access
Semantic Scholar
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
E. Roth, P. Moriarty, J. Bergeron, G. Langslet +4 more
2016Atherosclerosis120 citations Open access
Semantic Scholar
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.
C. Stefanutti, U. Julius, G. Watts, M. Harada-Shiba +9 more
2017Journal of Clinical Lipidology109 citations Open access
Semantic Scholar
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.
F. Kronenberg, S. Mora, E. Stroes, B. Ference +18 more
2023Atherosclerosis107 citations Open access
Semantic Scholar
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.
Stephen M. Amrock, P. Duell, T. Knickelbine, S. Martin +27 more
2017Atherosclerosis83 citations
Semantic Scholar
Lp(a) mass levels increase significantly according to APOE genotype: An analysis of 431,239 patients
P. Moriarty, S. Varvel, P. Gordts, J. Mcconnell +1 more
2017Arteriosclerosis, Thrombosis and Vascular Biology79 citations Open access
Semantic Scholar
Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
P. Duell, S. Gidding, Rolf L. Andersen, T. Knickelbine +23 more
2019Atherosclerosis77 citations Open access
Semantic Scholar
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis
P. Moriarty, L. Gorby, E. Stroes, J. Kastelein +2 more
2020Current Atherosclerosis Reports73 citations Open access
Semantic Scholar
Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
P. Moriarty, Jessica V. Gray, L. Gorby
2019Journal of Clinical Lipidology68 citations
Semantic Scholar
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry
Zahid S. Ahmad, Rolf L. Andersen, Lars H. Andersen, Emily C. O'Brien +22 more
2016Journal of Clinical Lipidology68 citations Open access
Semantic Scholar
Statin-associated muscle symptoms-Managing the highly intolerant.
J. Backes, J. Ruisinger, C. Gibson, P. Moriarty
2017Journal of Clinical Lipidology62 citations
Semantic Scholar
Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP).
M. Rizzo, A. Colletti, P. Penson, N. Katsiki +11 more
2023Pharmacological Research61 citations Open access
Semantic Scholar
Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
Louis St. L. O'Dea, J. Macdougall, V. Alexander, A. Digenio +9 more
2019Journal of the Endocrine Society55 citations Open access
Semantic Scholar
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
J. Tardif, E. Karwatowska-Prokopczuk, Eric St Amour, C. Ballantyne +14 more
2022European Heart Journal52 citations Open access
Semantic Scholar
Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry
M. Cuchel, P. Lee, L. Hudgins, P. Duell +29 more
2023Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease50 citations Open access
Semantic Scholar
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
L. Reeskamp, J. Kastelein, P. Moriarty, P. Duell +3 more
2019Atherosclerosis50 citations Open access
Semantic Scholar
Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis
Kamal Awad, D. Mikhailidis, P. Toth, S. Jones +8 more
2017Cardiovascular Drugs and Therapy49 citations
Semantic Scholar
Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
P. Willeit, C. Yeang, P. Moriarty, L. Tschiderer +3 more
2020Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease46 citations Open access
Semantic Scholar
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.
E. Karwatowska-Prokopczuk, J. Tardif, D. Gaudet, C. Ballantyne +9 more
2022Journal of Clinical Lipidology45 citations Open access
Semantic Scholar
Apolipoprotein C-III Inhibition with Volanesorsen in Patients with Hypertriglyceridemia (COMPASS): a Randomized, Double-Blind, Placebo-controlled Trial
I. Gouni-Berthold, V. Alexander, A. Digenio, R. Dufour +7 more
2017Atherosclerosis Supplements44 citations
Semantic Scholar
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
M. Roe, Qian H. Li, Deepak L. Bhatt, V. Bittner +15 more
2019Circulation43 citations Open access
Semantic Scholar
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)
M. Safarova, P. Moriarty
2023Current Atherosclerosis Reports40 citations
Semantic Scholar
Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.
M. Boffa, S. Stranges, N. Klar, P. Moriarty +2 more
2018Journal of Clinical Lipidology40 citations
Semantic Scholar
Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a)
M. Koren, P. Moriarty, J. Neutel, S. Baum +9 more
2020Circulation28 citations
Semantic Scholar
Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a).
Don P. Wilson, M. Koschinsky, P. Moriarty
2021Current Opinion in Endocrinology, Diabetes & Obesity27 citations
Semantic Scholar
Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis
E. S. Harris, H. Meiselman, P. Moriarty, A. Metzger +1 more
2018Journal of Scleroderma and Related Disorders24 citations Open access
Semantic Scholar
Statin therapy in athletes and patients performing regular intense exercise - Position Paper from the International Lipid Expert Panel (ILEP).
N. Katsiki, D. Mikhailidis, Gani Bajraktari, A. Miserez +68 more
2020Pharmacological Research23 citations Open access
Semantic Scholar
Effectiveness of a Novel ω -3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia A Randomized Clinical Trial
K. Maki, H. Bays, F. Aguilera, Glenn Gould +7 more
202122 citations
Semantic Scholar
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.
P. Moriarty, P. Thompson, C. Cannon, J. Guyton +10 more
2020Journal of Clinical Lipidology22 citations Open access
Semantic Scholar
Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial
V. Bittner, M. Szarek, P. Aylward, Deepak L. Bhatt +17 more
2018Atherosclerosis Supplements20 citations
Semantic Scholar
Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein(a)
Anne K. Nugent, Jessica V. Gray, L. Gorby, P. Moriarty
2020Journal of Clinical Cardiology19 citations Open access
Semantic Scholar
Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
S. Baum, T. Sampietro, D. Datta, P. Moriarty +5 more
2019Journal of Clinical Lipidology19 citations Open access
Semantic Scholar
Variability in Potency Among Commercial Preparations of Berberine
R. Funk, R. Singh, Robert D. Winefield, Sylvie E. Kandel +3 more
2017Journal of Dietary Supplements16 citations Open access
Semantic Scholar
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study
V. Devonshire, A. Feinstein, P. Moriarty
2016BMC Research Notes16 citations Open access
Semantic Scholar
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
P. Moriarty, Klaus G. Parhofer, Stephan P. Babirak, Emil M. deGoma +10 more
2016Journal of Clinical Lipidology15 citations Open access
Semantic Scholar
Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease.
R. Heinl, Heather M. Tennant, J. Ricketts, C. Rice +4 more
2017Journal of Clinical Lipidology14 citations
Semantic Scholar
Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit.
G. Hovingh, A. Goldberg, P. Moriarty
2017Journal of Clinical Lipidology14 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Tsimikas×11
Invite
S. Tsimikas — researcher profile on SciRah
S. Baum×10
Invite
S. Baum — researcher profile on SciRah
E. Stroes×8
Invite
E. Stroes — researcher profile on SciRah
G. Watts×8
Invite
G. Watts — researcher profile on SciRah

×7

Invite

P. Thompson — researcher profile on SciRah

Invite

P. Duell — researcher profile on SciRah

Invite

M. Banach — researcher profile on SciRah

Invite

E. Bruckert — researcher profile on SciRah

Invite

D. Gaudet — researcher profile on SciRah

M. Koschinsky×5

Invite

M. Koschinsky — researcher profile on SciRah

E. Steinhagen-Thiessen×5

Invite

E. Steinhagen-Thiessen — researcher profile on SciRah

Invite

Z. Fras — researcher profile on SciRah